- Home
- AQST vs ZVRA Comparison
AQST vs ZVRA Comparison
Compare AQST & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | ZVRA |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | 142 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.0M | 472.9M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AQST | ZVRA |
|---|---|---|
| Price | $4.07 | $10.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $9.00 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 2.0M | 859.4K |
| Earning Date | 06-08-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | $67,430,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $14.23 | $333.64 |
| Revenue Next Year | $58.36 | $44.19 |
| P/E Ratio | ★ N/A | $7.71 |
| Revenue Growth | 0.77 | ★ 350.91 |
| 52 Week Low | $2.20 | $6.19 |
| 52 Week High | $7.55 | $13.16 |
Technical Indicators
Market Signals| Indicator | AQST | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 63.42 |
| Support Level | $3.69 | $8.31 |
| Resistance Level | $4.46 | $12.14 |
| Average True Range (ATR) | 0.21 | 0.45 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 30.09 | 62.45 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.